BUILD A PORTFOLIO

INFECTIOUS DISEASE

EntraTympanic, LLC
INFECTIOUS DISEASE

EntraTympanic, LLC

This proprietary device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year. 80% of all children under the age of three suffer from this ailment, and current U.S. CPT reimbursement represents a $4 billion domestic opportunity. Worldwide, the potential rises to $40 billion for the disposable component of Entra Tympanic’s EToscope™.

Minimum Raise
$3,500,000
TYPE
Medical Device
PROBLEM
80% of all children under age three suffer acute otitis media or middle ear infections. These account for nearly half of all pediatric doctor visits and more than half of all antibiotics prescribed to U.S. children. These drugs cause adverse side effects, contribute to rising drug resistance and disrupt the gut flora that regulate our autoimmune and gastro-intestinal systems.
goal
Provide a new standard of care for treating middle ear infections that provides immediate pain relief, accelerates recovery from other symptoms and eliminates the use of systemic antibiotics.

Device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year

MINIMUM RAISE
$3,500,000
Infectious Disease

Hsiri Therapeutics
Infectious Disease

Hsiri Therapeutics

New antibiotics target life-threatening infections of drug-resistant organisms like Pseudomonas and Acinetobacter. The Company has developed two distinct classes of compounds and a platform technology. Together, these enable Hsiri to use existing generic drugs to develop new antibiotics directed at specific bacteria species (also including Mycobacterium avium). The U.S. market for these antibiotics exceeds $3 billion.

Minimum Raise
$3,000,000
TYPE
Therapeutic
PROBLEM
Antibiotic resistance has become a serious problem in the U.S. and abroad. More than 23,000 Americans die every year from antibiotic-resistant infections, and a lack of new antibiotic development exacerbates the problem. As bacteria continue to mutate and adapt, the need for more targeted antibiotics will grow just as quickly.
goal
Human life span has increased dramatically in the past century, largely due to infection control. Hsiri intends to sustain this increase by innovating a series of antibiotics capable of combating infectious diseases that now resist or will soon become resistant to current drugs.

New antibiotics target life-threatening infections of drug-resistant organisms like Pseudomonas and Acinetobacter

MINIMUM RAISE
$3,000,000
Cardiovascular

AblaCor Medical Corporation
Cardiovascular

AblaCor Medical Corporation

AblaCor’s proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF). The progressive impact of AF affects an estimated 6M people in the US and tens of millions worldwide. While traditional Pulmonary Vein Isolation for AF often requires repeated procedures, AblaCor’s CircumBlator™ maximizes ablator-tissue contact for a one-touch solution.

Minimum Raise
$1,000,000
TYPE
Medical Device
PROBLEM
Of the 100,000 ablations annually performed in the U.S. for AF, 40% are repeated 1-2 times. This often stems from poor ablator-tissue contact, one of the biggest limitations of current ablation technology.
goal
Develop an ablation catheter technology that maximizes ablator-tissue contact for effective treatment of AF with the initial procedure.

Proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF)

MINIMUM RAISE
$1,000,000
Epilepsy

Insero Health, Inc
Epilepsy

Insero Health, Inc

Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy. Success with drugs that treat a range of catastrophic, Orphan epilepsies like Infantile Spasms and Lennox Gastaut Syndrome, Insero intends a therapy for Dravet Syndrome to become its first clinical candidate compound. The company has used recent, molecular learning to screen and develop compounds which control seizures in animal models of Dravet.

Minimum Raise
$4,000,000
TYPE
Therapeutic
PROBLEM
Epilepsy afflicts 1% of the population, and while many recently developed drugs become billion-dollar a year sellers, most people with epilepsy still have little control of their seizures. One severe, Orphan variant is Dravet Syndrome, in which children begin life normally but suffer many seizures a day by early childhood. Language and cognitive dysfunction increase progressively. Existing therapies fail to control seizures, and many worsen the cognitive deficit.
goal
Take our lead compound into early treatment trials in children with Dravet Syndrome, and then partner with a major pharmaceutical company to complete development and gain approval by the FDA and other regulatory bodies internationally. Insero has already developed a large amount of safety and tolerability data on our lead compound. If a small study in children with Dravet suggests efficacy in controlling seizures, it will generate acquisition interest from the pharmaceutical industry.

Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy

MINIMUM RAISE
$4,000,000
Alzheimer's

Neurotez, Inc.
Alzheimer's

Neurotez, Inc.

Developing recombinant human Leptin as a therapy for Alzheimer's Disease (AD) and as a preventative for those at risk. The human hormone and protein Leptin has a large number of receptors in the brain’s memory centers. The protein’s levels often decline in AD patients, and their cognitive deterioration correlates strongly with a decrease in Leptin circulation. The protein is neuroprotective, improves cognition and Neurotez expects it to reduce the pathological hallmarks of Alzheimer’s disease – plaques and tangles. Leptin replacement therapy represents a relatively risk-reduced approach to drug development.

Minimum Raise
$4,000,000
TYPE
Therapeutic
PROBLEM
AD is the primary cause of cognitive impairment among the elderly. Its economic toll alone exceeds $100B annually, with immeasurable social costs. Alzheimer’s affects as many as 50% of those 85 and older, and up to 5 million people in total. Current medicines only offer moderate, limited duration relief of certain symptoms.
goal
Meaningfully decelerate disease progression in AD patients by replenishing their low leptin levels.

Developing a recombinant human Leptin therapy for Alzheimer's Disease and as a preventative for those at risk

MINIMUM RAISE
$4,000,000
Cancer

NeOnc Technologies, Inc.
Cancer

NeOnc Technologies, Inc.

Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers. Currently, drug delivery to the brain and spinal cord requires oral or intravenous administration. In all such systemic approaches, the blood brain barrier significantly hampers efficacy. Nasal brain delivery bypasses this inhibitor with direct, non-invasive access. NeOnc Technologies (NTI) is working in partnership with a pharmaceutical company to conduct a Phase I/II trial on their lead compound NEO100, for patients suffering recurrent, malignant gliomas.

Minimum Raise
$1,000,000
TYPE
Therapeutic
PROBLEM
Malignant gliomas prove 98% fatal for patients within 12-18 months of diagnosis. In 2012, the U.S. reported over 21,000 new cases of primary central nervous system (CNS) cancer. According to NIH National Cancer Institute (NCI), over 200,000 new cases of non-primary brain tumors in the U.S. required treatment in [that same year].
goal
Develop and expand the use of intranasal treatment for all cancers of the brain, central nervous system, nasal and respiratory system using perillyl alcohol and its derivatives in addition to and combined with other drugs.

Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers

MINIMUM RAISE
$1,000,000
Alzheimer's

DiamiR, LLC
Alzheimer's

DiamiR, LLC

Noninvasive technology for early detection and monitoring of Alzheimer's disease affecting 5.4M Americans. DiamiR develops proprietary noninvasive tests based on analysis of organ-enriched microRNAs in blood for early discovery of Alzheimer’s, other neurodegenerative diseases and cancer. In January 2014, the company announced validation of promising microRNA biomarkers for Mild Cognitive Impairment, an early stage of dementia including Alzheimer’s disease.

Minimum Raise
$2,000,000
TYPE
Diagnostic
PROBLEM
Data indicates that Alzheimer’s currently affects 5.4M Americans, at an annual healthcare cost of $200B. No disease-modifying drugs exist, and failures of drugs in development likely owe to massive neuronal death preceding advanced dementia. Existing diagnostic tools like imaging and spinal fluid analysis are expensive, invasive and unsuitable for primary screening.
goal
Provide accessible, cost-effective, noninvasive diagnostics for the early stages of Alzheimer’s disease. Early detection will permit early therapeutic intervention and more efficient patient enrollment into clinical trials. It will also enable more effective treatment, as well as better planning options for patients and caregivers.

Noninvasive technology for early detection and monitoring of Alzheimer's disease affecting 5.4M Americans

MINIMUM RAISE
$2,000,000
Kidney Disease

GLG Pharma, LLC
Kidney Disease

GLG Pharma, LLC

Combine advanced diagnostics and proprietary drugs to target ADPKD and p-STAT3 mediated cancers. The company is developing STAT3 inhibitors for ADPKD. These inhibitors also work particularly in reversing cancer cells resistant to chemotherapy. No alternatives currently exist for either condition, and GLG’s protocol can both improve quality of life and extend lifespan by 10-15 years.

Minimum Raise
$3,000,000
TYPE
Diagnostic,Therapeutic
PROBLEM
ADPKD has no known reliable therapy, and many p-STAT3 mediated cancers become resistant to chemotherapy.
goal
Create a lead compound that is well tolerated, displays superior bio-distribution and works in combination therapy to shut down ADPKD cell metabolism and reproduction.

Combine advanced diagnostics and proprietary drugs to target ADPKD and p-STAT3 mediated cancers

MINIMUM RAISE
$3,000,000

Poliwogg Products

Invest in the present and the future of health through the Poliwogg products.

Companies

Our online marketplace introduces you to private companies looking to transform healthcare. By expanding the number of accredited investors a private company can have, the JOBS Act makes these investment opportunities available at lower minimums.

MORE

Indexes

We are building indexes that represent many of the sub-economies of healthcare.

MORE

Funds

The Poliwogg Funds are sector specific publicly registered venture funds.

MORE

About Us

Watch CEO Greg Simon Explain the Importance of Poliwogg, the Crowd and Investing in Young Healthcare Companies - July 6, 2013

Welcome to Poliwogg, an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that measure the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical.  Our mission is to transform...

MORE

Poliwogg News

April 4, 2014

Invest in What You Know

MORE
January 30, 2014

Eager to “democratize” healthcare investing, Poliwogg gives the crowd new ways to join in

MORE
January 27, 2014

SoCalBio Elects Veteran Life Sciences Investor Joseph A. Boystak to Board of Directors

MORE
January 17, 2014

Health investing firm opens new Santa Monica, CA, office

MORE
January 13, 2014

MedTech Crowdfunding site Poliwogg Announces Partnership with Epilepsy Foundation, Alpha 1 Foundation

MORE
January 13, 2014

Epilepsy Foundation and Poliwogg Partner to Accelerate New Therapies for People Living with Seizures

MORE

CANCEL

Bloomberg Business Week
Business Wire
CNBC
CROWDFUND INSIDER
Elsevier Business Intelligence
FierceBiotech
GEN News
MoneyNews
PRWeb
The Burrill Report
The IN VIVO Blog
Xconomy